Metastatic Hormone Refractory Prostate Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
- Healthcare IT
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease.
Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form of cancer that affects men. In most of the cases, cancer remains confined to prostate gland, even after treatment. Hence, it is usually difficult and very painful to treat prostate cancer. The diagnostic tests may preliminary include deep study of patient’s history and reasons of pain. Afterwards, the diagnosis of metastatic hormone refractory prostate cancer is carried out by utilizing imaging studies, such as, CT scan, MRI, bone scanning, and PET scanning. Biopsy test is also used for diagnosis and confirmation of the disease. Moreover, rising level of prostate-specific antigens (PSA) in a patient treated with prostate cancer indicates that the disease has returned.
The market of metastatic hormone refractory prostate cancer is segmented on the basis of therapies and treatments available, such as, radiation therapy, chemotherapy, and cryosurgery. Radiation therapy mainly includes high energy X-rays or gamma-rays that are used to destroy the tumors. Hormone therapy is considered as the major therapy to treat metastatic hormone refractory prostate cancer. Major hormones used for the treatment of metastatic hormone refractory prostate cancer include goserelin (Zoladex), histrelin (Vantas), and leuprolide (Lupron) amongst others. Additionally, combined hormone therapy includes flutamide (Eulexin and others), nilutamide (Nilandron) and others. Chemotherapy is pharmacological treatment by using anti-cancer drugs either orally or parenterally. Major drugs used to treat this cancer include ketoconazole, dexamethasone, glucocorticoids, bisphosphonates, and finasteride (5-alpha reductase inhibitors) amongst others. Cryosurgery is also sometimes considered as the major therapy to treat metastatic hormone refractory prostate cancer. In addition, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The North American region is the most dominating market in the world, owing to rapidly growing incidences of prostate cancer and rising focus towards R&D to treat metastatic hormone refractory prostate cancer. On the other hand, Asia-Pacific and RoW are the most promising markets in the upcoming period, owing to rising awareness of prostate cancer, its chronic impact and treatments.
The market of metastatic hormone refractory prostate cancer is expected to steady growth rate during forecast period from 2014 – 2020. This growth is anticipated to be driven by various factors, such as, R&D practices running across the globe and high prevalence of prostate cancer. Owing to R&D practices, a number of drugs and formulations, such as, MDX-010 (Ipilimamab), MDV3100, Abiraterone and others are under pipeline studies and are expected to enter in the market during forecast period. Additionally, high prevalence of the disease is the major driver of the market growth. According to American Cancer Society estimates, approximately 233,000 new cases of prostate cancer are expected to diagnose in 2014, out of which, around 30,000 people may die due to prostate cancer. Hence, this high prevalence is the major driver of the market growth. In addition, rising awareness amongst the population for prostate cancer, and increasing medical infrastructure also support the growth of this market. However, high cost of R&D, diagnosis and treatment and lack of awareness in large number of countries (particularly belongs to Asia-Pacific and RoW region) are the major hurdles in the growth of this market.
The major players operating in this market include Novartis International AG, Pfizer, Inc., AstraZeneca plc, Genentech, Inc., Merck & Co, Inc. and Eli Lilly and Company amongst others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare IT
Healthcare ITGlobal mHealth Market Research Report 2016
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017